LifeMD Adds Eli Lilly’s Foundayo to Weight Management Program
Event summary
- LifeMD now offers Eli Lilly’s Foundayo (orforglipron), a once-daily oral GLP-1 therapy for weight management, approved by the FDA on April 1, 2026.
- Foundayo is available through LifeMD’s integration with LillyDirect, with a starting self-pay price of $149 per month.
- Patients with eligible commercial insurance may pay as little as $25 per month, and Medicare coverage is anticipated to begin July 2026.
- LifeMD’s weight management program includes virtual consultations, diagnostic testing, and educational resources.
The big picture
LifeMD’s integration of Eli Lilly’s Foundayo reinforces its position as a leading virtual care provider for weight management, expanding its portfolio of branded GLP-1 therapies. The move aligns with the broader trend of telemedicine platforms enhancing their offerings with FDA-approved medications to attract and retain patients. The strategic partnership with LillyDirect streamlines access, potentially increasing patient adherence and satisfaction.
What we're watching
- Market Positioning
- How LifeMD’s addition of Foundayo will affect its competitive stance against Novo Nordisk and other weight management providers.
- Patient Adoption
- The pace at which patients transition to Foundayo from other GLP-1 therapies, given its oral administration and pricing structure.
- Regulatory Dynamics
- Whether Medicare coverage expansion in July 2026 will drive further demand for Foundayo through LifeMD’s platform.
Related topics